Appearances can be deceptive

Marketing Authorisations

Memantine: poor evaluation and uncertain benefit in Alzheimer's disease

Psychometric scales in dementia

Pegylated interferon: chronic hepatitis C: advantageous for some patients, but more data needed

Liposomes, pegylation, and pegylated liposomes

Paracetamol + tramadol: no advance

Tadalafil: slightly more convenient, but poorly assessed in organic disorders

Imatinib: chronic myeloid leukaemia, first-line option: favourable findings to be confirmed

Imatinib and second-line treatment of chronic myeloid leukaemia: what long-term effects?

Type B botulinum toxin

Intravenous iron

Telmisartan + hydrochlorothiazide

Adverse Effects

Adverse effects of BCG vaccination

Glitazones and hepatitis and cardiac risks (continued)

Valvular heart disease with pergolide

Serious cutaneous reactions to amifostine

Neuropsychiatric adverse effects: coxibs too

Reviews

Intradermal BCG: partial protection against tuberculosis in children; unproven efficacy of multipuncture administration

Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease

Outlook

Drug advertising: the smokescreen of bibliographic references

Clinical guidelines are not immortal

Data protection: an anti-generic weapon

Heroin prescription in Europe

Errors in ambulatory medicine: research is in its infancy

Forum

Prevention of pulmonary embolism (continued)